Ad
related to: rnase-l inhibitor drugs
Search results
Results from the WOW.Com Content Network
Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA). Examples include: motexafin gadolinium. [1] hydroxyurea [2] fludarabine, cladribine, gemcitabine, tezacitabine, and triapine [3] gallium maltolate ...
Ribonuclease L or RNase L (for latent), known sometimes as ribonuclease 4 or 2'-5' oligoadenylate synthetase-dependent ribonuclease, is an interferon (IFN)-induced ribonuclease which, upon activation, destroys all RNA within the cell (both cellular and viral) as well as inhibiting mRNA export.
6059 24015 Ensembl ENSG00000164163 ENSMUSG00000058355 UniProt P61221 P61222 RefSeq (mRNA) NM_002940 NM_001040876 NM_015751 RefSeq (protein) NP_001035809 NP_002931 NP_056566 Location (UCSC) Chr 4: 145.1 – 145.13 Mb Chr 8: 80.41 – 80.44 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse ATP-binding cassette sub-family E member 1 (ABCE1) also known as RNase L inhibitor (RLI) is an ...
Ribonuclease inhibitor (RI) is a large (~450 residues, ~49 kDa), acidic (pI ~4.7), leucine-rich repeat protein that forms extremely tight complexes with certain ribonucleases. It is a major cellular protein, comprising ~0.1% of all cellular protein by weight, and appears to play an important role in regulating the lifetime of RNA .
For instance, by conjugating the RNA aptamer to a drug compound, the RNA aptamer can act as a targeted delivery system for that drug. [7] Such RNA aptamers are known as ApDCs. [7] Additionally, through conjugation to radioisotope or a fluorescent dye molecule, RNA aptamers may be useful in diagnostic imaging. [7] [104] [105]
They found multiple small molecule inhibitors of the HIV-1 Tat—TAR system that recognized the bulge, lower stem, or loop region of the TAR RNA. One of the compounds discovered, 2,4,5,6-tetraaminoquinozaline, binds to the loop region of TAR, downregulates cellular Tat transactivation, and ultimately inhibits HIV-1 replication. [12]
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
Efficacy was evaluated in a single-arm cohort of an open-label, multicenter trial (SNDX-5613-0700, NCT04065399; AUGMENT-101) in 104 adult and pediatric participants (at least 30 days old) with relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene translocation. [3]
Ad
related to: rnase-l inhibitor drugs